在结膜黑色素瘤中降低环林激酶抑制剂p16INK4a和p27的下调
Emerentienne Sarrasin1, Elea Lalys1, Katya Nardou1
1Department of Ophthalmology, Jules-Gonin Eye Hospital, FAA, University of Lausanne, Lausanne, Switzerland.
Investigative ophthalmology & visual science
|January 29, 2026
概括
在结膜黑色素瘤 (CJM) 中,p16INK4a和p27的损失与 nevi相比显著. 这些循环林依赖性激酶抑制剂可能有助于诊断,恢复p16INK4a功能可能会降低CJM的攻击性.
科学领域:
- 在瘤学瘤学.
- 皮肤病学 皮肤病学
- 分子生物学分子生物学
背景情况:
- 像p16INK4a,p27和p21这样的循环素依赖性激酶抑制剂 (CDKI) 的丧失与黑色素瘤的进展有关.
- 了解结膜色素细胞增殖中的CDKI表达对于诊断和治疗策略至关重要.
研究的目的:
- 评估p16INK4a,p27和p21在结膜瘤,结膜色素细胞内皮瘤 (C-MIN) 和结膜色素瘤 (CJMs) 中的表达.
- 在CJMs中探索p16INK4a的基因组,RNA和蛋白质水平之间的相关性.
- 通过针对p16INK4a.研究潜在的治疗策略.
主要方法:
- 免疫组织化学被用来分析p16INK4a,p27和p21的表达在51个结膜,38个C-MIN和49个CJM中.
- 在CJM样本上进行了全基因组/外基因组测序和RNA测序.
- 用DNA甲基转移酶抑制剂对CJM细胞系进行治疗,以评估其对p16INK4a表达和增殖的影响.
主要成果:
- 与内维相比,在CJM中观察到p16INK4a和p27的显著下调.
- 没有发现CDKN2A突变,但基因组改变 (同卵性/异卵性损失) 和转录后/翻译后修改影响了p16INK4a的表达.
- 用DNA甲基转移酶抑制剂治疗上调了p16INK4a,并减少了CJM细胞系中的增殖.
结论:
- 在CJM中p16INK4a和p27的下调可以帮助从结膜瘤的组织病理差异诊断.
- 在CJM中p16INK4a损失是多因素的,涉及基因组,表观遗传和翻译后机制.
- 恢复p16INK4a功能是一个潜在的治疗途径,可以减少CJM的攻击性.
相关概念视频
Protein Kinases and Phosphatases
15.1K
Proteins undergo chemical modifications that trigger changes in the charge, structure, and conformation of the proteins. Phosphorylation, acetylation, glycosylation, nitrosylation, ubiquitination, lipidation, methylation, and proteolysis are various protein modifications that regulate protein activity. Such modifications are usually enzyme-driven.
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
15.1K
Protein Kinases and Phosphatases
4.5K
4.5K
Receptor Downregulation in MVBs
2.8K
Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
2.8K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
529
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
529
Eukaryotic Transcription Inhibitors
11.0K
Certain biochemical processes, such as embryonic development and cell growth regulation, depend on the repression of specific genes. DNA binding proteins known as eukaryotic transcription inhibitors regulate the repression of gene expression in eukaryotes. The presence of these inhibitors at the required location and time in the cell is triggered by the presence of hormones and additional signals from other cells.
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
11.0K
Receptor Tyrosine Kinases
18.6K
Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
18.6K


